Pebble's Mission

The planet will soon need to support ten billion people – three billion more than today. It’s a future that requires immediate actions to create a foundation for more sustainable food supplies and better disease control.
Pebble Labs is committed to solving these global challenges. We bring scientists and researchers from around the world to our Los Alamos laboratory campus, collaborating to accelerate the science that creates real-world solutions. We move with urgency, sharing our learning and breakthroughs to solve some of the world’s biggest challenges as rapidly as possible.
At the heart of what we do is the application of innovative science to develop rationally-designed disruptive technologies to address the greatest agricultural, health and environmental challenges facing the globe.
We believe our research and breakthroughs can save millions of lives and allow people everywhere to prosper, with science-based, planet-friendly solutions to make the world a better place. That’s why the brightest minds in the world come to work at Pebble Labs.  They know their work is valued and creates a meaningful contribution to a better world.
shrimp_mermaidbiologo_black_background
sunflower_ironleaflogo_black_background
mosquito_littleflylogo_black_background
bulb_benchworkslogo_black_background

Our Teams

Michael Harrison

CEO, Chairman of the Board
Michael currently serves as CEO to a large private Ag Biotech company and has 35 years of experience in investment banking with interests in resource, energy and biotechnology sectors.
Michael has severed as CEO of two companies that he lead to successful exits totalling in excess of $2 billion. He has also served on the Board of Directors for numerous international publicly listed companies. He is also directly responsible for raising in excess of U.S. $1 billion in funding for private and publicly traded companies.

Dr.Richard Sayre

Chief Science Officer
Dr. Richard Sayre has extensive biotech experience in universities, national laboratories and the private sector.
In Nature journal, Dr Sayre is mentioned as one of the top 5 crop scientists who could change the world.
Dr. Sayre is the author of over 170 biotechnology papers and patents, with over 9,000 citations and received over U.S. $100 million in grant funding for various projects.

Edward Cheung

Chief Development Officer
Edward has over 20 years of experience in global investment banks, including JPMorgan, Lehman Brothers and Credit Suisse, advising on equities and derivatives to institutions, hedge funds and sovereign wealth funds. He is experienced in setting up new businesses, including a trading division at a U.S. bank and board member of several startups. He holds a BSc in economics from University College London and a master’s degree in property valuation & law from London Cass Business School.

Kimberly Harrison

Vice President
Kimberly Harrison has 25 years experience as an entrepreneur across industries. Kimberly is experienced in strategy, product development, VC funding, patents, distribution/licensing, and government relations.
She has served on numerous international product certifications and standardization committees.

Jon Bloodworth

Chief Operating Officer
Jon Bloodworth has three decades of senior executive management and legal experience in disruptive technologies, with an emphasis on intellectual property protection and licensing, commercial negotiations, finance and venture development.
Jon holds a law degree and is an active member of the State Bar of California.

Dr. Anne Lo

Director of Strategic Development
Dr. Anne Lo trained as a veterinary surgeon and worked in a number of clinical positions. She subsequently joined management consulting firm Bain & Co in London, before moving to a strategy role with WorldPay.
Dr. Lo was most recently with Horizons Ventures based in Hong Kong, where she primarily covered science and healthcare investments. Dr. Lo received her BSc and BVM&S degrees from the University of Edinburgh and PhD from the University of Cambridge.

David Smalley

General Counsel
David Smalley has 17 years practicing corporate and securities law, providing legal services for financing private and public companies.
David is a director of a number of Capital Pool Companies listed for trading on the TSX-Venture Exchange in Canada.
David advises CEOs on their financing and business strategies; provides corporate, commercial and securities legal services.

David Chu

Chief Financial Officer
David Chu brings more than 20 years of global experience in financial management, investment analysis and entrepreneurship.
Recently David was with Early Growth Financial Services as a Consulting CFO and Principal, providing senior financial and strategic guidance as well as accounting management to dozens of early stage and technology-oriented clients.
David received his MBA from Harvard Business School and graduated magna cum laude from Georgetown University with a BSBA degree in Finance and International Business.

Dr. Rick DeRose

VP of Product Development
Over 25 years’ experience in Ag Biotechnology at Syngenta and Bayer developing innovation strategies for R&D projects.
Co-inventor of the first commercialized Roundup Ready Corn varieties.
Awarded the ASPB 2017 Innovation Prize for Agricultural Technology for successfully translating discovery research into demonstrable, real-world outcomes on Global Agriculture.

Dr. Tichafa “Tich” Munyikwa

VP of Regulatory Affairs
Over 20 years’ experience at major Ag-Biotech companies as a Senior Research Scientist and Global Regulatory Expert.
Fields include: Agribusiness, Biotechnology, Plant Molecular and Cell Biology, Biologicals, RNA interference, Genome Editing, and Synthetic Biology.
Received his Ph.D. in Cell and Molecular Biology from Wageningen University (The Netherlands).

Aristobulo “Tobo” Loaiza

VP of Business Development
Over 10 years at BASF in various technical and commercial roles including heading business development and technology evaluation for BASF’s Venture Capital/NewBusiness group in the Americas. Extensive value chain knowledge in Chemicals, Aquaculture, Ag, Food, Coatings and Oil and Gas.
Received his PhD in Biochemistry & Chemistry from Purdue University and Masters Degree in BioInorganic Chemistry from UCLA.

Ron Deutsch

Chief People Officer
Ron brings more than 30 years of experience in senior leadership roles within the technical and professional service industries, ranging from Fortune 100 organizations to early-stage entrepreneurial companies. Ron holds a bachelor’s degree with honors from the University of California, Los Angeles, a Juris Doctor degree from Southern Methodist University and a Fellowship in Labor Relations from the National Public Employers Labor Relations Association at Cornell University’s School of Industrial & Labor Relations.

Peter J. McDonough

Chief Strategy Officer
Peter has driven global success across numerous consumer industries serving in senior leadership roles at Diageo, Procter & Gamble, Gillette, Duracell, Black & Decker and Braun. In his most recent corporate role, he served as Diageo North America President, Chief Marketing & Innovation Officer. His professional experience spans seven industries, leading teams on three continents and includes time as a faculty member at University of Canterbury’s Graduate School of Business (New Zealand) and in advisory roles such as the Board of Directors at the AdCouncil of America and Effies Worldwide. Peter is an alumnus of Cornell University with an MBA from the Wharton School of Business.

David S. Kerr

Senior Advisor
Dr. David Kerr is an Intellectual property lawyer partner at Berg Hill Greenleaf Ruscitti, LLP with a joint JD/MBA and graduate degrees in the molecular biosciences. David helps secure and enforce intellectual property rights in countries throughout the world. David specializes in intellectual property litigation, including both enforcement and defense of traditional intellectual property rights such as patent, trademark and copyrights, as well as unfair competition, misappropriation and trade secret matters. He also provides strategic business guidance to emerging bio-technology companies.

Miro Cernetig

Strategic Advisor
Miro Cernetig is the founder of Catalytico ~ ideas in motion, a brand-creation agency that builds and amplifies unique ideas and brand strategies. Since 2010, Miro and his team have worked with leaders in real estate, agrifoods, biotech, property development, energy & mining, transportation & aviation, philanthropy, international exporters, entertainment, IPOs and government.
Miro is also an award-winning journalist and filmmaker, working across Canada, North America and Asia, as The Globe and Mail’s bureau chief in Beijing, New York, The Arctic & Alberta and Vancouver, and The Toronto Star’s Quebec correspondent. Miro’s work in film, print and digital mediums has appeared in The Economist, The CBC, The NYT, The Toronto Star, The Globe and Mail, The Vancouver Sun, National Geographic, Channel Four and many other platforms. He is also co-founder of CityAge, an international platform bringing together thousands of leaders building the world’s cities and a sustainable future for us all.

Thomas Walek

Communications
Coming Soon

Dr. Tatiana Vinogradova-Shah

VP Research – Mermaid Division
Bio Coming Soon

Dr. Pedro Costa Nunes

VP Research – BenchWorks Division
Dr. Costa Nunes received is PhD in Biology from the University of Lisbon, Portugal. He is a Plant Cell and Molecular Biologist with expertise in the fields of epigenetics, DNA damage response and smRNA mediated regulation of gene expression.

Dr. Konstantinos Lymperopoulus

VP Research – LittleFly Division
Bio Coming Soon

Dr. Tawanda Zidenga

VP Research
Dr. Zidenga brings more than 15 years of experience in advanced studies in plant tissue culture, metabolic engineering and plant secondary metabolism research. He received his PhD in plant cellular and molecular biology from the Ohio State University and a bachelor’s degree in crop science from the University of Zimbabwe.

Dr. Erick LeBrun

VP Research – Parallax Division
Dr. LeBrun has a PhD in Biology from Baylor University, where he focused on microbial ecology, metagenomics, and bioinformatics. His expertise is in using genetics to explore microbial community dynamics and novel bioinformatics analyses to turn large genomic datasets into meaningful information for real-world application.

Dr. Norman G. Lewis

Norman G. Lewis, Regents Professor, Washington State University, is a Fellow of the Royal Society of Edinburgh and other learned societies. His internationally recognized successful academic and industrial expertise spans more than 50 years in chemistry, biochemistry, molecular biology, and genetic engineering. He has published in excess of 250 papers, with an h-index over 50. Professor Lewis’ research program has largely been supported by US and Canadian federal agencies, including DOE, NASA, NSF, NIH, USDA and NSERC, as well as by various companies and foundations. He has also served his profession in various senior editorial positions ( e.g. Phytochemistry), as well as Director of the Institute of Biological Chemistry at WSU, and in other leadership roles in numerous scientific societies for a period spanning 25 years or so.

Dr. William Black

Dr. Black is Professor in the Dept of Microbiology, Immunology and Pathology of Colorado State University. His Arthropod-borne and Infectious Diseases Laboratory works on the mosquito Aedes aegypti, the primary vector to humans of the virus that causes dengue fever, yellow fever and chikungunya. This includes trying to identify the genes that determine why one population is susceptible to infection while other populations are resistant. As there are currently no vaccines to prevent dengue viruses and no drugs to treat it, the goal has been to identify genes in Ae. aegypti that enable it to survive insecticides. This will help public health workers to identify which insecticides to use in the event of a dengue fever, yellow fever or chikungunya outbreak.

Dr. David Kerr

Dr. David Kerr is an Intellectual property lawyer partner at Berg Hill Greenleaf Ruscitti, LLP with a joint JD/MBA and graduate degrees in the molecular biosciences. David helps secure and enforce intellectual property rights in countries throughout the world. David specializes in intellectual property litigation, including both enforcement and defense of traditional intellectual property rights such as patent, trademark and copyrights, as well as unfair competition, misappropriation and trade secret matters. He also provides strategic business guidance to emerging bio-technology companies.

Dr. Hector Quemada

Dr. Hector Quemada is the Director of Biosafety Resource Network at the Donald Danforth Plant Science Center. Hector is an independent consultant for the Gates Foundation and Monsanto. Hector is an expert in regulatory affairs and sits on Little Fly Lab’s Scientific Advisory Board.

Dr. Amanda Simcox

Dr. Amanda Simcox is the Professor for the Department of Molecular Genetics at Ohio State University, where she studies EGF receptor signaling in the early wing disc to decipher the complete gene regulatory network that operates in this short period of time to specify the adult wing and body wall of the thorax. The finding that these conserved signaling pathways are operating leads to an expectation that the circuit in the wing will be used in other tissues and animals. Amanda sits on Little Fly Lab’s Scientific Advisory Board.

Michael Harrison

CEO, Chairman of the Board
Michael currently serves as CEO to a large private Ag Biotech company and has 35 years of experience in investment banking with interests in resource, energy and biotechnology sectors.
Michael has severed as CEO of two companies that he lead to successful exits totalling in excess of $2 billion. He has also served on the Board of Directors for numerous international publicly listed companies. He is also directly responsible for raising in excess of U.S. $1 billion in funding for private and publicly traded companies.

Jason Adler

Managing Member, Gotham Green Partners
Jason Adler has over 20 years of experience investing across multiple asset classes as the CEO and co-founder of a New York-based investment firm. Jason is an experienced private investor across both venture capital and early stage businesses and director of a Canadian-listed public company.

Edward Cheung

Director, Chief Development Officer
Edward Cheung has over 20 years experience in global investment banks including JPMorgan, Lehman Brothers and Credit Suisse, advising on equities and derivatives to institutions, hedge funds and sovereign wealth funds. Edward is experienced in setting up new businesses including a trading division at a US bank and board member of several startups. He holds a B.Sc. in Economics from University College London and a Masters degree in Property Valuation & Law from London Cass Business School.

Kimberly Harrison

Director
Kimberly Harrison has 25 years experience as an entrepreneur across industries. Kimberly is experienced in strategy, product development, VC funding, patents, distribution/licensing, and government relations. She has served on numerous international product certifications and standardization committees.

Eugene Hodgson

Director
Eugene Hodgson is an accomplished and agile Senior Executive in both private industry as a banker, financial and public policy advisor. He has significant expertise in renewable energy, technology and natural resources, connecting businesses and financing sources. Eugene is an experienced negotiator with First Nations groups and a strategic Board member for a number of business and community associations. This includes being Director and Audit Chair of Pebble Labs Inc., Maxtech Ventures Inc., Rover Metals Inc, Red Fund Capital Corp and Trait Biosciences Inc.

David Smalley

Director Chief Counsel
David Smalley has 17 years practicing corporate and securities law, providing legal services for financing private and public companies. David is a director of a number of Capital Pool Companies listed for trading on the TSX-Venture Exchange in Canada. David advises CEOs on their financing and business strategies; provides corporate, commercial and securities legal services.